Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative `A` (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative `A` was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative `A` could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative `A` highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.

KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY

KING ABDULLAH UNIVERSITY OF SCIENCE &amp; TECHNOLOGY

Anti-cancer lead molecule

Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

plumbagin/rakovina

Anti-cancer lead molecule

Treatment of prostate carcinoma

Treatment of prostate carcinoma

Treatment of prostate carcinoma

Treatment of prostate carcinoma

Nejúplnější databáze léčivých bylin podložená vědou